Cell delivery to the infarcted heart has emerged as a promising therapy, but is limited by very low acute retention and engraftment of cells. The objective of the study was to compare a panel of biomaterials to evaluate if acute retention can be improved with a biomaterial carrier. Cells were quantified post-implantation in a rat myocardial infarct model in five groups (n=7-8); saline injection (current clinical standard), two injectable hydrogels (alginate, chitosan/β-glycerophosphate) and two epicardial patches (alginate, collagen). Human mesenchymal stem cells (hMSCs) were delivered to the infarct border zone with each biomaterial. At 24 hours, retained cells were quantified by fluorescence. All biomaterials had superior fluorescence to saline control, with 8 and 14-fold increases with alginate and chitosan/β-GP injectables, and 47 and 59-fold increases achieved with collagen and alginate patches, respectively.
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Introduction
In the US one person suffers a myocardial infarction (MI) every 34 seconds [1] . As a result, approximately one million people are discharged from hospital with heart failure annually [1] . With advancements in the acute treatment of myocardial infarction death rates have improved dramatically, but strategies for treating those who go on to develop ventricular dysfunction are lacking. Stem cell therapy is a promising candidate for treatment of acute myocardial infarction and ischemic cardiomyopathy. One of the major hurdles in successful clinical translation of cardiac cell therapy is poor cell survival, retention and engraftment in the infarcted heart -a critical requirement for effective treatment. Tissue retention of cells is persistently low. Various factors contribute to this phenomenon and include exposure of cells to ischemia and inflammation, mechanical washout of cells from incessantly beating myocardium, flushing by the coronary vasculature, leakage of cell suspension from the injection site and anoikis [2] [3] [4] . The overwhelming majority of cell displacement and death occurs within the first few days after delivery. Therefore, an early assessment of cell retention is likely to be strongly predictive of longer-term retention and engraftment [4] . Reported rates of cell retention in animal hearts, where cells were administered intramyocardially as a simple suspension in saline (the current clinical standard) or media, vary with administered cell type and cell number, along with the time of analysis post-delivery and the time of delivery post-MI. However, retention is typically very poor. For example, delivery of mesenchymal stem cells (MSCs) to infarcted rat or porcine hearts in the manner described above (media/saline suspension, intramyocardial injection) has yielded results as low as 11% retention at 90 minutes and 0.6% retention at 24 hours [5] [6] [7] .
Studies in human subjects confirm the low retention phenomenon [8, 9] . Regardless of cell type or delivery route, acute retention of less than 10% is generally reported with saline/media. Studies with different cell types show a strong correlation between engraftment rate and long-term functional benefit [10] [11] [12] supporting the hypothesis that new strategies to improve delivery and engraftment of cells could increase therapeutic benefit.
The development of cell therapy as a feasible therapeutic option in the treatment of myocardial infarction (MI) is in part dependent on new strategies to enable viable cells to remain in infarcted tissue and exert therapeutic benefit for extended periods.
Investigated strategies have included efforts to manipulate the cells themselves, such as induction of pro-survival signals through heat-shock or transduction of administered cells with pro-survival factors like Bcl-2 [4, 13] . However, these interventions do not directly address the physical factors which result in dispersion of cells or anoikic death as a result of poor attachment site presentation. An alternative is to utilize a biomaterial approach, whereby a biomaterial is used to provide a surrogate extracellular matrix for administered cells to enhance cellular cohesion and retention at the infarct site.
Biomaterials can potentially confer a measure of protection from noxious insults like inflammation and ischemia and reduce cell death due to anoikis. To date, there exist two major biomaterial approaches to myocardial cellular delivery, namely cell-loaded syringeable hydrogels which are injectable directly into the myocardial wall, or cellseeded patches which are affixable to the epicardial surface [14] . In this study, as summarized in Figure 1 , we compare a panel of biomaterials: an injectable chitosan/β-glycerophospate (chitosan/β-GP) hydrogel, an injectable alginate hydrogel, a collagen patch and an alginate patch for their ability to increase cellular retention in the myocardium within the acute phase post-MI, and enhance cell viability in the conditions of hypoxia/ischemia mimic, typically present in infarcted tissue. The goal was to evaluate whether material-based delivery of cells is generally superior to a saline control, and so we chose to evaluate dissimilar materials, delivered by different methods. These biomaterials have differing concentrations of adhesion ligands and different mechanical and chemical properties. We chose to use hMSCs for this study as Results with these cells may be applicable to the myocardial delivery of cells in general, since the largely non-specific principle of mechanical retention of cells at the site of administration underlies the ability of biomaterial carriers to enhance cellular retention.
Materials and Methods

Formulation of biomaterial carriers
Chitosan/β-GP gels were prepared by stirring ultrapure 95% deacetylated chitosan hydrochloride (CL214, Novamatrix, Oslo) in deionized water at pH 8-8.5 until dissolved and subsequently adding beta-glycerophosphate dropwise, as previously described (15) . The solution was kept on ice until use, and used within 12 hours. Alginate (PRONOVA) was modified with a peptide containing the RGD sequence to a degree of substitution (DS) of 20 to promote adhesion of cells as previously described [16] . In Injectable gels were prepared from lyophilized stocks as previously described [17] . For the alginate patches, alginate was reconstituted in MES buffer under sterile conditions and cross-linked by standard carbodiimide chemistry using 1-ethyl-(dimethyl aminopropyl) carbodiimide, 1-hydroxybenzotriazole hydrate (HOBT) and the bifunctional cross-linker adipic acid dihydrazide (AAD), (ratio of AAD: reactive groups on polymer; 1:20), as previously described [18, 19] . 6mm diameter, 2mm thick discs were cut out using a biopsy punch, then rinsed three times daily in deionized water for three days, frozen at -20°C overnight, then lyophilized for at least three days and stored in a dessicator until use. Collagen scaffolds, 6mm diameter, 3 mm thick, were fabricated using a lyophilisation process as previously described [20] . Briefly, Type 1 microfibrillar bovine tendon collagen (CollagenMatrix; USA) was blended (Ultra Turrax T18 Overhead blender, IKA Works Inc., Wilmington, NC) at a constant 4ºC in 0.05M acetic acid. The collagen slurry was added to a stainless steel pan and exposed to a freeze-drying cycle with a freezing temperature of -10°C to generate an average pore size of 300 μm. Discs of 6 mm were cut using a biopsy punch. Size of patches and injection volumes was optimized in vitro (Fig 2a,b) .
Culture Studies
hMSCs (AllCells, USA) were encapsulated in chitosan/β-GP or alginate gels at a density of 100,000 cells/100μL gel (1 x 10 6 cells/mL) and 100μL was added to a hanging well cell culture insert with a pore size of 1µm, suitable for insertion into a 48-well plate (Scaffdex, Finland). Gels (n=3) were allowed to thermogelate (chitosan/β-GP) or ionically crosslink (alginate) at 37°C for 30 minutes. 700µL of normal hMSC growth media was then added per well (400µL basolaterally, 300µL apically). Cells were also seeded onto dry collagen or alginate patches (n=3), at 100,000 cells per patch, on one side. In addition, cells were also seeded in 2D at a density of 100,000 cells per well in adherent 6-well plates (n=3). Inserts, scaffolds or cells in 2D were cultured under normal conditions for 24hrs, at which point they were placed in a hypoxia chamber (1% O 2 , 5% CO 2 , and 94% N 2 ) and in low nutrient media consisting of glucose-and serum-free Dulbecco's modified eagle medium (DMEM) supplemented with 1mM 2-deoxyglucose, to inhibit glycolysis, to mimic the harsh environment of infarcted tissue [21] . All samples were analyzed for cell viability by live/dead staining at 0hrs, 24hrs, 48hrs, day 4, and day 6 by live/dead staining. Staining was carried out as per manufacturer's instructions (Live/dead cell viability assay, Life Technologies, MA, USA). Stained samples were imaged by confocal microscopy on a Leica LSM710 confocal microscope using Zen software (Carl Zeiss, USA) at three randomly chosen fields of view per each of three replicates per group, at 10X magnification for a 100m z-stack using calcein and ethidium channels for excitation. A minimum of approximately 100 cells per field were counted at time 0. Imaris software (Bitplane, CT, USA) was utilized to count live cells in each z-stack. The "surface object" module was used to generate a 3-D representation of 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 the field, and surface objects were created on an intensity value on a per channel basis, hMSCs or GFP-hMSCs were DiD-labeled (Invitrogen) and seeded in 6-well plates at 100,000 cells per well . After 48-hours cell viability was assessed via trypan blue exclusion assay. DiD-labelled cells were imaged with a Xenogen In Vitro Imaging System 100 (IVIS) with the following settings; fluorescent imaging, excitation filter 640nm, emission filter 680nm, binning of 8, field of view 6.5 and f-stop 2. Fluorescence was compared to non-labeled control using Living Image ® software (PerkinElmer, MA, USA). 2-way ANOVA with a Holm-Sidak post-hoc analysis was used to determine statistical significance between groups. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 65
MI model and cell delivery
Rats underwent myocardial infarction as previously described 12 were optimized ex-vivo. For the infarction surgery, the chest wall was opened to expose the heart and the pericardium was removed. A guide suture was used to gently manipulate the heart for ligation of the left anterior descending artery and placement of patches or injections (Fig 2c) . Myocardial blanching was apparent after ligation of the LAD, confirming infarction (Fig 2d) . Patches were attached to the myocardium, cellseeded side towards the epicardium, at the infarct border zone with a single 6.0 prolene suture (Fig 2e) , and all remained in place 24 hours later (Fig 2f) . DiD-labeled GFPhMSCs were encapsulated in or seeded on biomaterial carriers (400,000 cells/60μL gel/saline immediately before administration. 400,000 cells per patch 12 hours prior to surgery to allow cell attachment). Cells were maintained on ice for not more than 30 minutes before myocardial administration. 60μL of gel or saline (the current clinical standard) was injected into the infarct border zone at three injection sites (20μL per injection, 400,000 cells total) with a 100μL microsyringe and a 27G needle. The needle remained in the myocardium for approximately 30 seconds after each injection to minimize leakage. After cell delivery/patch implantation the chest retractor was removed, each of the muscle/fascial layers was closed and sutured with a Vicryl 4.0 suture. A small opening was left to permit access to the chest cavity for a modified chest drainage tube consisting of a flexible tube attached to a 30mL syringe. This was used to evacuate the chest cavity of air and restore negative pleural pressure prior to final closure of the chest wall. The skin layer was closed and sealed with 9mm stainless steel skin closure clips. Anesthesia was removed, animals were ventilated with pure O 2 and monitored until signs of non-assisted breathing were observed and then ventilation was completely removed. Animals were allowed to recover on a heated mat until ambulatory. 5mL of warm 0.9% saline was injected subcutaneously and animals had access to moist food to aid rehydration and recovery following surgery. Analgesia (0.05mg/kg buprenorphine, administered subcutaneously) was administered preoperatively and every 12 hours thereafter until sacrifice. Mortality was approximately 10%.
Tissue Harvesting and quantification of cellular retention by IVIS imaging
24 hours after cell delivery animals were anaesthetized with an injection of ketamine (40-80 mg/kg body weight) and xylazine (5-10 mg/kg body weight), and then intubated as described above and ventilated with air at the above settings. Heparin was injected intra-peritoneally at a dose of 1 unit/g body weight. Rats underwent a bilateral thoracotomy, to completely expose the thoracic cavity. An incision was made below the diaphragm, and then the diaphragm was cut (serving as a method of secondary euthanasia). Ribs on each side were cut, and the anterior chest wall was lifted using forceps on the xiphoid process. The anterior chest wall was fully removed. Using two forceps, the thymus was carefully removed to reveal the aortic arch and great vessels.
A purse string suture was placed around the aorta, an incision was made beside the left subclavian branch of the aorta, and a feeding needle was inserted, so that it remained above the aortic valve. The suture was secured above the ball of needle. A 27G needle was inserted into the left ventricle of the heart through the apex and 5ml of PBS was flushed through the ventricle and feeding needle to remove ventricular blood. The heart was excised and imaged on the Xenogen IVIS with fluorescent imaging (excitation filter 640nm, emission filter 680nm). The heart was then attached to a perfusion rig using the feeding needle, which enabled perfusion through the coronary vessels at physiological pressure. The heart was perfused with saline for 2 minutes to flush blood from the tissue. The heart was then perfused with a cadmium/potassium/TRIS solution for 30 seconds to arrest the heart in diastole and close the aortic valve, ensuring that fluid perfused through the coronary vessels (0.05mol/L tris(hydroxymethyl)aminomethane and 0.01mol/L cadmium chloride solution was brought to pH 9-10, then immediately before use and added to a 1M potassium chloride solution in a 2:1 ratio and brought to pH 7). Finally the heart was perfused with 4% paraformaldehyde for 15 minutes to fix the tissues. The heart was then cut into 4 transverse sections using a scalpel blade.
These were stored in 4% paraformaldehyde overnight at 4°C. In order to compare 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 signal at 0 hours and 24 hours, freshly excised hearts were perfused with saline as previously described, and gels or patches containing 400,000 cells were implanted as described for the surgical procedures. Ex vivo hearts were immediately imaged as described above. Living Image® software (Perkin Elmer, MA, USA) was used to quantify fluorescence. A non-parametric ANOVA on ranks analysis was used to determine statistical significance between groups.
Autofluorescence measurements
In order to investigate potential sources of confounding autofluorescence, a cell-free infarcted heart, harvested at 24 hours was IVIS imaged, along with a sample of each of the biomaterials without cells. In Living Image ® software, a circular region of interest was drawn around the fluorescent area, and the total radiance was calculated for that region. In order to subtract background fluorescence, the radiance was calculated for a circle of the same size on the same area of an infarcted heart with no transplanted cells, and this background was subtracted.
Histological analysis
Fixed heart sections were transferred to 15% w/v sucrose for 2 hours at 4°C, before storage in 30% w/v sucrose overnight. Tissues were then snap-frozen in OCT medium, using liquid nitrogen-cooled isopentane and stored at -80°C in sealed containers until sectioning. OCT blocks were sectioned on a cryotome (CM 1950, Leica). The block containing the tissue slice of interest (containing epicardial patch or injection) was identified and sections were transferred to charged slides (Superfrost Plus, ThermoScientific). Each block was sectioned entirely, in 8m and 45msections. See 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64 Images were taken on a Zeiss LSM 710 confocal microscope. Samples were imaged at magnification of 6X or 12X and 63X, in the region of transplanted cells. DAPI and eGFP channels were used for excitation of the sample. A z-stack of 45m was taken and the maximum intensity projection was acquired with Zen software (Carl Zeiss Microscopy, USA).
Results
In order to measure in vitro cell viability on biomaterial substrates in a mimic of the hypoxic/ischemic environment of an infarct, hMSCs were encapsulated in chitosan/β-GP or alginate hydrogel or seeded on collagen or alginate patches and cultured in hypoxia/ischemia mimic for up to 6 days. As expected, cell viability diminished in vitro over 6 days on all growth substrates in this mimic of hypoxic/ischemic conditions ( Figure   3a ). However, cell viability was higher in biomaterials when compared to monolayer culture by day 6. This was corroborated by representative images taken at day 6, which demonstrated greater levels of cell viability in chitosan/β-GP and alginate hydrogels compared with 2D culture (Figure 3a,b) .
The methodology for analyzing cell retention in the myocardium was next validated.
After ischemic injury endogenous fluors such as flavins, lipofuscin and other blood derived pigments can accumulate in tissue, contributing to an autofluorescence which can confound fluorescent signals from membrane labelers or fluorescent antibodies [23] . Natural biomaterials can also produce autofluorescence which could confound IVIS measurements [24] . To address this issue, the autofluorescent properties of an unaltered infarcted heart, 24 hours after ligation and empty biomaterial carriers were investigated. Negligible fluorescence was emitted from the unaltered infarcted heart (Figure 4a,d,f) , or empty biomaterial carriers at DiD-measurable wavelengths ( Figure   4b ,c,d,f). The specific fluorescence from cell numbers ranging from 100,000-400,000, in increments of 100,000, were also quantified (Figure 4 Hearts injected with DiD-GFP hMSCs delivered via alginate and chitosan/β-GP gels demonstrated a significant 8-fold and 14-fold mean increase in fluorescent signal, respectively, when compared to saline-injected hearts (Figure 6a,b) . Similarly, 47-fold and 59-fold increases were found for collagen and alginate patches, respectively (Figure 6a,c) . IVIS images of all samples are in the online Supplemental Material, Figure S4 . These results were corroborated by a qualitative histological analysis. In saline-injected hearts very few hMSCs were visible in the myocardium, whereas substantially more cells were apparent in alginate or chitosan/β-GP-injected hearts. In hearts with affixed patches, a high density of cells was observed within the patch structure ( Figure 6d ). As the absolute fluorescence is attenuated by depth in tissue, the signal at 24 hours was normalized to the signal from each cell-loaded biomaterial in the heart at 0 hours. Cell retention from 0-24 hr in all biomaterial treated hearts was superior to that of the saline control, with no significant difference between the individual biomaterials from time 0 to 24 hr (average of 50-62% for biomaterials,9% for saline control; Figure 6e ).
Discussion
This study presents a direct head-to-head comparison of diverse biomaterials delivered to different sites, specifically to compare acute cell retention, which to our knowledge has not been studied previously. While previous studies have corroborated our findings that biomaterial delivery vehicles can enhance cellular retention [25] [26] [27] , this is the first study that directly compares four distinct biomaterials. We also evaluate injectable alginate gel for intra-myocardial delivery of cells, a biomaterial that has progressed to phase II clinical trials for acellular myocardial repair based on promising results both preclinically and in phase I trials [28] . Given pre-existing clinical safety and efficacy data and the potential for enhancement of cellular retention demonstrated here, alginate possesses significant translational potential. This study also shows much higher cellular retention values for chitosan/β-GP hydrogel than previously published [29, 30] . In vitro, gels likely enabled higher viability in hypoxia/ischemia mimic at 6 days due to the protective effect of total encapsulation or decreased metabolic rate in 3D culture.
These increases in cell retention are in line with the work presented in other studies which successfully used in situ gelling hydrogel delivery vehicles to enhance myocardial cellular retention, both in the acute phase and longer term retention, although not all studies report substantial enhancements. Indeed, the large increases in retention we report here are superior to those achieved at the same timepoint in many studies. A sample of studies is presented in Table S1 (Appendix A: Supplementary Data) where reported cell retention data following intramyocardial injection of a hydrogel carrier vehicle is compared with saline delivery, for a variety of cell types (fold changes are gel over saline or media delivery).
Cell-loaded biomaterials address the issue of mechanical dispersion of cells from the injection site, which is a major source of cell loss within the myocardium. Poor cell retention is likely to be a major factor underlying the failure of cell-based therapies for MI to achieve consistent and substantial efficacy to date [31, 32] . Since numerous studies have shown that the majority of cells are lost within 24 hours, here we elected to study acute cell retention as a primary endpoint, with the rationale that this would be predictive of longer term retention and efficacy. This rationale is corroborated by several pre-existing studies which correlate enhancement of acute myocardial cellular retention with longer term retention and consequent increases in efficacy [10] [11] [12] 29, 30] . For example, Liu et al. reported a 1.5-fold increase in acute cell retention of ADSCs encapsulated in chitosan/β-GP/HEC, 24 hours post administration, compared to cells delivered in saline. However, an 8-fold increase in retention was observed when hydrogel-injected animals were imaged at day 28, demonstrating that gains in acute retention also resulted in robust increases in retention at later timepoints, which appeared to be related to greater cell loss from saline-injected hearts over time [29] .
Despite the current challenges in achieving high levels of cell retention, engraftment and survival in vivo, outcomes to date demonstrate benefit [33] . Our study shows a foldincrease in fluorescent signal of approximately ten and fifty for biomaterial injectables and epicardial patches respectively, and a significantly superior maintenance of cells in the first twenty four hours for all biomaterials compared to a saline control. Given these favorable numbers, this increase in retention may translate to a large increase in clinical benefit.
Despite initial expectations for cardiogenic potential of transplanted cells, in most studies the number of transplanted cells that actually differentiate into cardiomyocytes is not large enough to account for the observed clinical benefits, due to low engraftment and cardiogenic differentiation of transplanted cells. The paracrine hypothesis may explain this, whereby transplanted cells release soluble factors that help regenerate the heart [34, 35] . Bone marrow derived cells such as mesenchymal stem cells have been shown to release factors involved in cardiac repair (cytokines, growth factors and chemokines) especially under hypoxic conditions [34] . This hypothesis was supported by Gnecchi et al, who demonstrated the ability to recreate the effects of cell therapy with conditioned media [35] . There are a number of proposed mechanisms for such paracrine effects including modulation of inflammatory responses, upregulation of angiogenesis and protection of cardiac cells, recruitment of endogenous stem cells and promotion of cardiac cell cycle re-entry [33] . If we relate this to our study, epicardial patches may be able to exert enhanced efficacy compared with the current clinical standard, through paracrine signaling due to their facilitation of superior cell retention.
The effect may be limited by diffusion across the epicardial surface, requiring further study, but it is encouraging that we can increase the number of cells remaining on the surface of the heart 50-fold compared to the clinical standard, suggesting one could conceivably enable efficacy by more than this factor without the need for transepicardial cellular migration.
We elected to use immunocompetent animals, despite the delivery of xenograft cells, since other authors have previously reported minimal staining for monocytes and macrophages as a result of intramyocardial injection of hMSCs in immunocompetent rats at 24 hours post-injection [36] , suggesting a significant immune response had not yet been mounted at this early stage.
The biomaterials studied differ in terms of mechanical properties, fabrication, rates of degradation, chemical composition and porosity, yet all provided similar levels of delivered cell retention after 24 hours (although some washout at injection site means less cells are delivered at 0 hours with injectable hydrogels). A physical, non-cytotoxic, porous scaffold may fulfill the basic criteria for effective enhancement of acute cellular retention, as measured here. Dissimilar materials were compared here to establish the generality of these findings. All four tested biomaterials can mediate cell adhesion (alginate was RGD functionalized; collagen contains native integrin binding sites; cationic chitosan can mediate adsorption of adhesive proteins), suggesting this may be a key facet of a successful cell delivery system. However, the exact relationship between biomaterial composition, cell adhesion and long-term fate, and therapeutic efficacy has not yet been elucidated, in the context of cellular cardiomyoplasty, and will be the focus of future work.
Both physical forms of biomaterials tested here are likely to have utility and could potentially fulfill patient-specific niches. The comparison of two forms of alginate as an injectable and epicardial patch cell carrier is valuable in comparing delivery methods without varying material and delivery parameters independently. Injectable hydrogels may enable immediate and direct myocardial delivery, while epicardial patches may facilitate better retention and sustained release as cells migrate into the underlying myocardium over time, since they aren't subjected to the same mechanical stresses as intramyocardial injections. While epicardial patches could be used to cover large infarcts, injectable gels could be used to target multiple smaller focal areas.
Intramyocardial delivery is more invasive within the myocardium itself, but potentially less invasive overall, if delivery is possible from the endocardial side utilising percutaneous injection catheters. Epicardial deposition of patches may require a minithoracotomy, although some of the studied materials show potential for delivery in a minimally invasive manner [37, 38] , thereby increasing potential for clinical effect. Both approaches demonstrate therapeutic applicability to the wider spectrum of infarctionmediated myocardial damage and should be considered for future cell therapy applications. 3  4  5  6  7  8  9  10  11  12  13  14  15  16  17  18  19  20  21  22  23  24  25  26  27  28  29  30  31  32  33  34  35  36  37  38  39  40  41  42  43  44  45  46  47  48  49  50  51  52  53  54  55  56  57  58  59  60  61  62  63  64  65 
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